AstraZeneca nabs three small-molecule drugs from X-Chem

Waltham, MA-based X-Chem says that AstraZeneca ($AZN) has agreed to pick up licenses on a trio of small-molecule programs generated during their 2-year-old partnership. No deal terms were announced, but X-Chem says the pharma giant grabbed a drug aimed at an oncology PPI target, a respiratory/inflammation PPI target, and an antibacterial target. "Our on-going two-year, multi-target collaboration with X-Chem is focused on discovering leads to several of AstraZeneca's drug targets using X-Chem's innovative small molecule discovery platform," said Mike Snowden, vice president of discovery sciences at AstraZeneca. "The collaboration has enabled generation of novel chemical series for three of our key therapeutic programs and is an important part of our small molecule discovery strategy." Release

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.